Substituting clozapine for olanzapine in psychiatrically stable parkinson's disease patients: Results of an open label pilot study

Clinical Neuropharmacology

Volumn 21, Issue 5, 1998, Pages 285-288

  Friedman, Joseph H ^a   Goldstein, Susanne ^b   Jacques, Carol ^b  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b NONE

Author keywords

Atypical antipsycotic drugs; Clozapine; Dopamimetic psychosis; Olanzapine; Parkinson's psychosis

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CLOZAPINE; LEVODOPA; OLANZAPINE; PERGOLIDE; RISPERIDONE;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS;

AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; PIRENZEPINE; PSYCHOSES, SUBSTANCE-INDUCED; TREATMENT OUTCOME;

EID: 0031723842     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Friedman JH. The management of levodopa psychoses. Clin Neuropharmacol 1991;14:283-295.
2. Rabey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD. Lowdose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995;45:432-434.
3. Chacko RC, Hurley RA, Harper RG, et al. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995;7:471-475.
4. Auzou P, Ozsancak C, Hannequin D, et al. Clozapine for the treatment of psychosis in Parkinson's disease: a review. Acta Neurol Scand 1996;94:329-336.
5. Wagner ML, Defilippi JL, Manza MA, Sage JI. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996;8:276-280.
6. Auzou P, Ozsancak C, Hannequin D, et al. Clozapine for the treatment of psychosis in Parkinson's disease: a review. Acta Neurol Scand 1996;94:329-336.
7. Factor SA, Molho ES, Podskalny GB, Brown D. Parkinson's Disease: Drug Induced Psychiatric States. Adv Neurol 1995;65:115-138.
8. Ruggieri S, De Pandis MF, Bonamartini A, et al. Low Dose of Clozapine in the Treatment of Dopaminergic Psychosis in Parkinson's isease. Clin Neuropharmacol 1997;20:204-209.
9. Wolters Cch, Hurwitz TA, Make E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990;40:832-834.
10. Marek K. Personal communication, 1996.
11. Casey DE. What makes a neuroleptic atypical? In Meltzer HY (ed), Novel Antipsychotic Drugs. New York, Raven Press, pp 241-251.
12. Baldessarini RJ, Frankenburg FR. Clozapine A Novel Antipsychotic Agent. N Eng J Med 1991;324:746-754.
13. Marder SR. Clinical experience with risperidone. J Clin Psychiatry 1996;57(suppl9):57-61.
14. Meco G, Allessandria A, Bonifati V, Giustini P. Risperidone for hallucination in levopdopa-treated Parkinson's disease patients (letter). Lancet 1994;343:1370-1371.
15. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease (letter). Lancet 1994;334:681.
16. Rich S, Friedman JH, Ott BR. Risperidone versus clozapine for the treatment of drug induced psychosis in Parkinson's patients. J Clin Psychiatry 1995;56:556-559.
17. Damecour CL, Turcotte JR. Therapeutic dilemma: psychosis and Parkinson's disease. Can J Psychiatry 1995;40:640-641.
18. Montgomery S, Beasley CM, Tye NC. Olanzepine: An open label study in schizophrenia. Vancouver, B.C. Second International Conference on Schizophrenia (7/19-7/22, 1992). Cited in Beaseley, Tollefson, Tran et al 1996. Lack of prolactin elevation with olanz.
19. Beasley CM jr, Tollefson G, Tran P, et al. Olanzapine versus Placebo and Haloperidol. Acute Phase Results of the North American Double-Blind Olanzapine Trial. Neuropsychopharmacol 1996;14: 111-123.
20. Beasley CM jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacol 1996;124:159-167.
21. Tollefson GD, Beasley CM jr, Tran PV, et al. Olanzapine Versus Haloperidol in the Treatment of Schizophrenia and Schizoaffective and Schizophreniform Disorders: Results of an International Collaborative Trial. Am J Psychiatry 1997;154:457-465.
22. Wolters E.Ch., Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-1087.
23. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: An aid to improved reliability. Psychopharmacol Bull 1988;24:112-117.
24. Fahn S, Elton RL, member of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fann S, Calne DB, Lieberman A, eds. Recent Developments in Parkinson's Disease. Florham Park, M.J.: Macmillan Health Care Information; 1987: 153-163.
25. Folstein MF, Fosstein SE, McHugh PR. "Mini-mental state": a practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
26. Hoehn MH, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
27. De Leon J, Stanilla JK, White AO, Simpson GM. Anticholinergics to Treat Clozapine Withdrawal. J Clin Psychiatry 1994;55:119-120.